CCM
ROIV icon

CTC Capital Management’s Roivant Sciences ROIV Stock Holding History

CTC Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$199K Buy
+27,000
New +$222K 0.42% 49

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CTC Capital Management's ROIV Position: Q1 2023 in Review

CTC Capital Management opened a new position in Roivant Sciences (ROIV) in Q1 2023: 27,000 shares worth $199K. The stake represents 0.42% of the portfolio and ranks #49 among its holdings.

147 funds tracked by Wall St. Rank hold ROIV as of Q1 2023.

  • CTC Capital Management held 27,000 shares of Roivant Sciences worth $199K as of Q1 2023.
  • Roivant Sciences was a new CTC Capital Management position in Q1 2023.
  • Roivant Sciences made up 0.42% of CTC Capital Management's portfolio in Q1 2023, its #49 holding.
  • 147 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.